BioCorRx Inc. (BICX)
OTCMKTS · Delayed Price · Currency is USD
0.3052
0.00 (0.00%)
At close: Apr 14, 2026
BioCorRx Revenue
In the year 2025, BioCorRx had annual revenue of $797.24K with 10,301.10% growth. BioCorRx had revenue of $-151.12K in the quarter ending December 31, 2025.
Revenue
797.24K
Revenue Growth
+10,301.10%
P/S Ratio
10.11
Revenue / Employee
265.75K
Employees
3
Market Cap
8.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 797.24K | 789.58K | 10,301.10% |
| Dec 31, 2024 | 7.67K | -81.50K | -91.40% |
| Dec 31, 2023 | 89.16K | -124.68K | -58.31% |
| Dec 31, 2022 | 213.84K | 165.57K | 342.99% |
| Dec 31, 2021 | 48.27K | -74.35K | -60.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veltex | 70.13M |
| Regional Health Properties | 52.37M |
| Selectis Health | 41.44M |
| Mid-Atlantic Home Health Network | 27.00M |
| Cardiff Lexington | 11.54M |
| Syra Health | 7.23M |
| Stem Cell Authority | 3.33M |
| Xcelerate | 2.70M |
BioCorRx News
- 4 months ago - BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th - GlobeNewsWire
- 5 months ago - Diamond Equity Research Releases Update Note on BioCorRx®, Inc. (OTCQB: BICX) - GlobeNewsWire
- 8 months ago - Diamond Equity Research Initiates Coverage on BioCorRx®, Inc. (OTCQB: BICX) - GlobeNewsWire
- 1 year ago - BioCorRx Reports Business Update for the Second Quarter of 2024 - GlobeNewsWire
- 2 years ago - BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia - GlobeNewsWire
- 2 years ago - BioCorRx Reports Business Update for 2023 - GlobeNewsWire
- 2 years ago - BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD - GlobeNewsWire
- 2 years ago - BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors - GlobeNewsWire